Flu vaccine and immunotherapy for early colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a flu vaccine directly into the tumor along with an immunotherapy drug (pembrolizumab) before surgery can help the immune system fight colorectal cancer better. It is for people with early-stage colorectal cancer that has not spread and who are scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has not spread (stage I to III) and is of a type called pMMR.
- You are scheduled for surgery to remove the cancer, and you have not had chemotherapy or radiation before surgery.
- You are 18 years or older.
- You are generally in good health (able to do daily activities) and have adequate blood, kidney, and liver function.
- You do not have an autoimmune disease (except well-controlled thyroid or type 1 diabetes), HIV, hepatitis B or C, or a condition requiring steroids or other immune-suppressing drugs.
- You have not had a severe allergic reaction to flu vaccines or their components, and you are not currently sick with a fever or infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink colon cancer and improve outcomes. It is for people with a specific type of colon cancer that is planned for surgery.
This study tests giving an immunotherapy drug (pembrolizumab) before surgery for people with early-stage colon cancer that has a specific genetic feature. The goal is to see if the drug can shrink the tumor enough to avoid more extensive surgery.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and porustobart) given before surgery for colon cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.